FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening TestInvestigational AI-powered multiomic test is being developed for adults ages 50-80 at high risk who are not currently participating in guideline-recommended lung cancer screening
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening –
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 –
